FOR US RESIDENTS ONLY
NOW APPROVED For the treatment of Dystrophic Epidermolysis Bullosa (DEB) in patients 6 months and older
Support & Resources

Additional Resources

Resources

Explore resources designed to support your VYJUVEK treatment journey

Below are some resources to better inform you and those in your care about treatment with VYJUVEK. Your Krystal Connect™ team can also provide additional dystrophic epidermolysis bullosa (DEB) education information.

Learn more about VYJUVEK™ from the patient brochure
VYJUVEK BROCHURE

Learn more about VYJUVEK including wound healing results.

Download Now
KRYSTAL CONNECT BROCHURE

An introduction to resources available to patients with DEB and their caregivers.

Download Now
A list of helpful questions to ask a doctor about VYJUVEK™ treatment
DOCTOR DISCUSSION GUIDE

A list of helpful questions to ask your doctor to have an informed discussion about VYJUVEK treatment.

Download Now
Download the VYJUVEK™ enrollment form and bring it to your doctor
ENROLLMENT FORM

Download this form and bring it to your doctor to start your VYJUVEK prescription.

Download Now

Support Organizations

You are not alone on your DEB journey. There are a number of organizations that provide support to individuals and families living with DEB. Here are some that might be a fit for you:

Events

Educational programs designed for you

Learn more about DEB and VYJUVEK from medical experts and members of the DEB community.

Register for Krystal Connect educational programs. View All Upcoming Events
INDICATION AND USAGE

VYJUVEK is a topical gel used to treat wounds in patients 6 months and older with dystrophic epidermolysis bullosa (DEB).

IMPORTANT SAFETY INFORMATION

VYJUVEK gel must be applied by a healthcare provider.

After treatment, patients and caregivers should be careful not to touch treated wounds and dressings for 24 hours. If accidentally exposed to the VYJUVEK gel, clean the affected area.

Wash hands and wear protective gloves when changing wound dressings. Disinfect bandages from the first dressing change with a virucidal agent, and dispose of the disinfected bandages in a separate sealed plastic bag in household waste. Dispose of the subsequent used dressings in a sealed plastic bag in household waste.

Patients should avoid touching or scratching wound sites or wound dressings.

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose. These are not all the possible side effects with VYJUVEK. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to the Sponsor at 1-844-557-9782.

  • Please see Important Safety Information above and click here for full Prescribing Information.
IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE

VYJUVEK is a topical gel used to treat wounds in patients 6 months and older with dystrophic epidermolysis bullosa (DEB).

IMPORTANT SAFETY INFORMATION

VYJUVEK gel must be applied by a healthcare provider.

After treatment, patients and caregivers should be careful not to touch treated wounds and dressings for 24 hours. If accidentally exposed to the VYJUVEK gel, clean the affected area.

Wash hands and wear protective gloves when changing wound dressings. Disinfect bandages from the first dressing change with a virucidal agent, and dispose of the disinfected bandages in a separate sealed plastic bag in household waste. Dispose of the subsequent used dressings in a sealed plastic bag in household waste.

Patients should avoid touching or scratching wound sites or wound dressings.

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose. These are not all the possible side effects with VYJUVEK. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to the Sponsor at 1-844-557-9782.

  • Please see Important Safety Information above and click here for full Prescribing Information.